Developer docs
API playgroundTry for free, no card

Search company profiles

OWC Pharmaceutical Research

Full company profile

uuid003fwd4

Namestring
OWC Pharmaceutical Research
Websiteurl
owcpharma.com
Company typeenum
Private
Founded yearint
2014
Short descriptiontext

OWC Pharmaceutical Research is a publicly traded (OTCQB: OWCP) Israeli micro-cap that was organized to develop cannabis-based pharmaceuticals through clinical research, but currently shows no active operations, with its website parked and no products, customers, or pipeline disclosed.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersRamat Gan, Israel
HQ citystring
Ramat Gan
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Keyword5 values
cannabis pharmaceuticals, clinical trials research, medical cannabis, cannabinoid therapeutics, pharmaceutical development
Industry2 codes
PRIMARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIADAA
Pain Relief & Anti-Inflammatory (Analgesics)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Cannabis Pharmaceutical Research
Social media profiles2 records
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

OWC Pharmaceutical Research conducts medical research and clinical trials aimed at developing cannabis-based pharmaceuticals and treatments. The company engages in pharmaceutical R&D centered on cannabinoid-derived therapeutic candidates, with operations based in Israel.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Cannabis-based pharmaceutical research and clinical trials
CategoryPharmaceutical R&D services
No data
Peers10 records
1Tetra Bio-Pharma
TypeDirect peer
Description

Canadian clinical-stage pharmaceutical company developing cannabinoid-derived prescription drugs and drug-device combinations. Closely comparable to OWC in target therapeutic applications and small clinical-stage pharmaceutical profile.

TypeBroad incumbent
Description

Global cannabis company with a fermentation-derived cannabinoid pharmaceutical pipeline. Comparable as a broad incumbent with pharmaceutical-grade cannabinoid development programs.

TypeBroad incumbent
Description

Major cannabis company with pharmaceutical and clinical research arms. Comparable as a broad incumbent pursuing cannabis-based pharmaceutical applications at significant scale.

TypeDirect peer
Description

Canadian life sciences company developing cannabinoid-derived pharmaceutical products. Comparable to OWC as a small public clinical-stage cannabis pharmaceutical developer.

TypeDirect peer
Description

Clinical-stage pharmaceutical company focused on inflammatory and fibrotic diseases, with prior cannabinoid programs. Comparable as a small clinical-stage pharma developing novel mechanism therapies in regulated markets.

TypeBroad incumbent
Description

Acquired GW Pharmaceuticals, the developer of Epidiolex, the first FDA-approved plant-derived cannabinoid prescription medicine. Comparable as the established leader in cannabis-derived prescription pharmaceuticals and the benchmark for OWC's therapeutic category.

TypeDirect peer
Description

Small U.S./Israel-based pharmaceutical company developing cannabinoid-based precision medicine for cancer and other indications. Closely comparable to OWC as a small clinical-stage cannabis pharma with an Israeli operational footprint.

TypeDirect peer
Description

Clinical-stage specialty pharmaceutical company developing transdermal cannabinoid therapeutics for neurological and psychiatric conditions. Directly comparable to OWC in terms of size, cannabinoid focus, and clinical-stage pharmaceutical development.

TypeBroad incumbent
Description

Canadian licensed producer with a medical cannabis division and pharmaceutical research partnerships. Comparable as a broader incumbent with medical-cannabis pharmaceutical development ambitions.

10Tilray Brands
TypeBroad incumbent
Description

Global cannabis company with pharmaceutical-grade cannabis production and clinical research operations. Comparable as a large-scale cannabis operator with pharmaceutical ambitions intersecting with OWC's stated focus.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OWC Pharmaceutical Research

Cannabis Pharmaceutical Researchowcpharma.com

OWC Pharmaceutical Research is a publicly traded (OTCQB: OWCP) Israeli micro-cap that was organized to develop cannabis-based pharmaceuticals through clinical research, but currently shows no active operations, with its website parked and no products, customers, or pipeline disclosed.

OWC Pharmaceutical Research firmographics

Firmographics
Name
OWC Pharmaceutical Research
Website
https://owcpharma.com
Company type
Private
Founded year
2014
Headcount range
1–10 employees
Short description
OWC Pharmaceutical Research is a publicly traded (OTCQB: OWCP) Israeli micro-cap that was organized to develop cannabis-based pharmaceuticals through clinical research, but currently shows no active operations, with its website parked and no products, customers, or pipeline disclosed.
Ownership category
akta.pro rank

OWC Pharmaceutical Research industry classification

Industry
Product category
Cannabis Pharmaceutical Research
NAICS
Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIADAA
Pain Relief & Anti-Inflammatory (Analgesics)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines

Keywords

  • Cannabis pharmaceuticals
  • Clinical trials research
  • Medical cannabis
  • Cannabinoid therapeutics
  • Pharmaceutical development

Where OWC Pharmaceutical Research is headquartered

Location

Headquarters

HQ city
Ramat Gan
HQ country
Israel
HQ region
Middle East

Markets served

OWC Pharmaceutical Research business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

OWC Pharmaceutical Research product offering

Product offering

Core offering

OWC Pharmaceutical Research conducts medical research and clinical trials aimed at developing cannabis-based pharmaceuticals and treatments. The company engages in pharmaceutical R&D centered on cannabinoid-derived therapeutic candidates, with operations based in Israel.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cannabis-based pharmaceutical research and clinical trials

Companies that use OWC Pharmaceutical Research

Customer profile

Ideal customer profiles1 record

OWC Pharmaceutical Research technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

OWC Pharmaceutical Research competitors and assessment

Company assessment

Direct peers

  • Tetra Bio-Pharma: Canadian clinical-stage pharmaceutical company developing cannabinoid-derived prescription drugs and drug-device combinations. Closely comparable to OWC in target therapeutic applications and small clinical-stage pharmaceutical profile.
  • Emerald Health Therapeutics: Canadian life sciences company developing cannabinoid-derived pharmaceutical products. Comparable to OWC as a small public clinical-stage cannabis pharmaceutical developer.
  • Corbus Pharmaceuticals: Clinical-stage pharmaceutical company focused on inflammatory and fibrotic diseases, with prior cannabinoid programs. Comparable as a small clinical-stage pharma developing novel mechanism therapies in regulated markets.
  • Cannabics Pharmaceuticals: Small U.S./Israel-based pharmaceutical company developing cannabinoid-based precision medicine for cancer and other indications. Closely comparable to OWC as a small clinical-stage cannabis pharma with an Israeli operational footprint.
  • Zynerba Pharmaceuticals: Clinical-stage specialty pharmaceutical company developing transdermal cannabinoid therapeutics for neurological and psychiatric conditions. Directly comparable to OWC in terms of size, cannabinoid focus, and clinical-stage pharmaceutical development.

Broad incumbents

  • Cronos Group: Global cannabis company with a fermentation-derived cannabinoid pharmaceutical pipeline. Comparable as a broad incumbent with pharmaceutical-grade cannabinoid development programs.
  • Canopy Growth: Major cannabis company with pharmaceutical and clinical research arms. Comparable as a broad incumbent pursuing cannabis-based pharmaceutical applications at significant scale.
  • Jazz Pharmaceuticals (formerly GW Pharmaceuticals): Acquired GW Pharmaceuticals, the developer of Epidiolex, the first FDA-approved plant-derived cannabinoid prescription medicine. Comparable as the established leader in cannabis-derived prescription pharmaceuticals and the benchmark for OWC's therapeutic category.
  • Aurora Cannabis: Canadian licensed producer with a medical cannabis division and pharmaceutical research partnerships. Comparable as a broader incumbent with medical-cannabis pharmaceutical development ambitions.
  • Tilray Brands: Global cannabis company with pharmaceutical-grade cannabis production and clinical research operations. Comparable as a large-scale cannabis operator with pharmaceutical ambitions intersecting with OWC's stated focus.

Market position

Customer concentration

OWC Pharmaceutical Research social profiles

Digital presence

OWC Pharmaceutical Research financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OWC Pharmaceutical Research leadership team

Management profile

Number of profiles

OWC Pharmaceutical Research funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OWC Pharmaceutical Research M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OWC Pharmaceutical Research

What does OWC Pharmaceutical Research do?

OWC Pharmaceutical Research conducts medical research and clinical trials aimed at developing cannabis-based pharmaceuticals and treatments. The company engages in pharmaceutical R&D centered on cannabinoid-derived therapeutic candidates, with operations based in Israel.

When was OWC Pharmaceutical Research founded?

OWC Pharmaceutical Research was founded in 2014. It employs 1 to 10 people.

Where is OWC Pharmaceutical Research based?

OWC Pharmaceutical Research is headquartered in Ramat Gan, Israel, in the Middle East region.

Who are OWC Pharmaceutical Research's main competitors?

Direct peers on record are Tetra Bio-Pharma, Emerald Health Therapeutics, Corbus Pharmaceuticals, Cannabics Pharmaceuticals and Zynerba Pharmaceuticals. Broad incumbents are Cronos Group, Canopy Growth, Jazz Pharmaceuticals (formerly GW Pharmaceuticals), Aurora Cannabis and Tilray Brands.

Does OWC Pharmaceutical Research have an API?

No public API is recorded for OWC Pharmaceutical Research.

What industry is OWC Pharmaceutical Research in?

OWC Pharmaceutical Research's product category is Cannabis Pharmaceutical Research. Its primary akta.pro industry code is HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development), with a secondary code of HLAIADAA, Pain Relief & Anti-Inflammatory (Analgesics). Its NAICS code is 325411 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireIf you purchased OWC Pharmaceutical Research Corp. stock between November 2016 and September 2017, you may be eligible for distribution from the Jeffrey Friedland Fair FundThe SEC filed a complaint against Jeffrey O. Friedland, Global Corporate Strategies LLC, and Intiva Pharma LLC for a nearly $7 million securities fraud scheme involving OWC Pharmaceutical Research Corp., an Israeli medical marijuana company. Friedland concealed his financial interest in OWCP while promoting the stock to investors, allowing him to sell his shares at artificially inflated prices between August 2014 and September 2017. A Final Judgment ordered $4,179,000 in disgorgement and civil penalties, which has been paid into a Fair Fund, and eligible investors who purchased OWCP stock between November 2016 and September 2017 can now file claims for distribution by June 6, 2022.PR NewswireOWC Pharmaceutical Research Corp. Announces A New Distribution Agreement With Can It Industries, Florida USOWC Pharmaceutical Research Corp. signed an international distribution agreement with Florida-based Can It Industries on September 14, 2020, for a 24-month initial phase covering distribution across multiple US states, territories, and regions in the Americas. The agreement grants Can It distribution rights for OWC's medical cannabis products in Florida, Puerto Rico, Arizona, Oklahoma, Native American Tribal Lands, Central America, the Caribbean, and South America. The companies intend to leverage Can It's manufacturing capabilities, distribution channels, and healthcare institution connections to bring OWC's pharma-grade medical cannabis products to patients throughout the Americas.PR NewswireOWC Pharmaceutical Research Corp. Letter to Shareholders for Upcoming Proxy VotingOWC Pharmaceutical Research Corp. announced that it will hold a shareholders meeting on August 31, 2020, to vote on a reverse split and increasing the authorized shares. The company aims to secure additional investments and stabilize financially by pursuing new equity and finalizing a business plan, potentially involving partnerships in the U.S. medical cannabis market.PR NewswireOWC Pharmaceutical Research Corp. Announces Special Meeting of StockholdersOWC Pharmaceutical Research Corp. announced it will hold a special meeting of stockholders on August 25, 2020 to vote on a reverse stock split at a ratio between 1:10 and 1:20. The company stated it needs the reverse split to raise funds from new investors, as it has no authorized share capital available, and warned that without shareholder approval it will likely be unable to secure the needed investment to execute its roadmap. OWC also disclosed it engaged investor relations firms and highlighted its USPTO patent for cannabis-based topical formulations issued in March 2020.PR NewswireOWC Israel's Patent for Cannabis Based Extracts and Topical Formulations for Use in Skin Disorders, Is Allowed for Issuance as a Patent in the USAOWC Pharmaceutical Research Corp., through its subsidiary OWC-Israel, announced that the United States Patent and Trademark Office issued a Notice of Allowance for a patent application related to cannabis-based extracts and topical formulations for skin disorders, including psoriasis. The patent adds to OWC's intellectual property portfolio and marks a milestone in its clinical development efforts.New Cannabis VenturesJeffrey Friedland Settles SEC Stock Promotion Fraud Charges for $4.18 Million – NCV MediaJeffrey Friedland settled SEC fraud charges, agreeing to pay over $4 million and a 10-year ban on penny stocks. The settlement includes $2.18 million in disgorgement and $2.0 million in penalties. He had profited nearly $6.5 million from selling 5.1 million shares of OWC Pharmaceuticals without disclosing compensation.PR NewswireOWC Pharmaceutical Research Corp. to Report Top Line Results (TLR) for a Safety Study on Its Cannabis-based TabletsOWC Pharmaceutical Research Corp. announced top line results from a clinical study comparing its Medical Grade Cannabis Orally Disintegrating Tablets (MGC-ODT) to Sativex® in healthy adult volunteers conducted at Sourasky Medical Center in Tel Aviv, Israel. The study found comparable pharmacokinetics, bioavailability, and safety profiles between both products, with similar incidence of treatment-related adverse events including hunger, thirst, dizziness, and dysgeusia. The company intends to apply to the Israel Ministry of Health to obtain necessary approvals to market MGC-ODT in Israel.PR NewswireOWC Pharmaceutical Research Received a Permit for a Cannabis Based Ointment Efficacy TrialOWC Pharmaceutical Research Corp. received approval from the Israeli Medical Cannabis Agency on July 18, 2019, to conduct an efficacy study with its cannabis-based topical ointment on psoriatic patients at Kaplan Medical Center in Israel. The company stated this is reportedly the first time the agency has issued a permit for treating psoriasis with a cannabis-based product. The study will proceed in two stages: first a pilot efficacy and dosage study, followed by a double-blind, placebo-controlled study.PR NewswireOWC Pharmaceutical Research Corp, Letter to ShareholdersOWC Pharmaceutical Research Corp, an Israeli developer of cannabinoid-based medical therapies, issued a shareholder letter summarizing 2018 achievements including completion of a safety study on their cannabis cream for skin disorders, development of a second-generation sub-lingual tablet, and a dosing study for their Multiple Myeloma cancer therapy program. The company raised $5 million through a preferred convertible offering from an institutional investor and announced plans for a reverse stock split. Upcoming clinical milestones include initiating a comparative safety and efficacy trial for their tablet in Q2 2019 and an efficacy trial for their cannabis cream in Q3 2019, pending regulatory approvals.PR NewswireOWC Pharmaceutical Research Corp. Reports Positive Safety Data From Phase 1 (Safety) Clinical Trial for Medical Grade Cannabis Ointment for Treatment of Skin DiseasesOWC Pharmaceutical Research Corp. reported positive Phase 1 safety data from a clinical trial of its medical grade cannabis MSG ointment (3% CBD, 3% THC) for treating skin diseases, with no severe adverse events observed across 46 healthy subjects in two stages conducted at Sheba Academic Medical Center in Israel between September 2017 and January 2019. The Phase 1 trial was a single-center, prospective, placebo-controlled study assessing safety and tolerability of single and repeated topical applications. The company plans to initiate a Phase 2 trial for psoriasis treatment in the third quarter of 2019.